Pipeline

TCT has developed an extensive portfolio of applications of its ground breaking technology platform and currently holds exclusive licenses for its fields.  We are currently developing applications through research programs targeting improvement of treatments for:

• Gaucher Disease (TCT-370) and other lysosomal disorders
• Inflammatory conditions - Targeting Monocyte Chemoattractant Protein-1 (MCP-1/CCL2)
• Low bone density conditions
• Metastatic lytic bone disease